Report Sections

See All Reports

  • HP:0002725: Systemic lupus erythematosus
  • Pneumonia (361) Abnormality of the cardiovascular system (36) Respiratory tract infection (36) Neoplasm (29) Hypoxemia (28) Diabetes mellitus (25) Depressivity (24) Thromboembolism (23) Acute kidney injury (22) Abnormal lung morphology (21) Anosmia (19) Hypertension (18) Abnormality of coagulation (15) Pulmonary embolism (15) Pulmonary fibrosis (15) Stroke (14) Arthritis (14) Interstitial pneumonitis (14) Myocardial infarction (12) Type II diabetes mellitus (12) Deep venous thrombosis (11) Rheumatoid arthritis (10) Leukemia (10) Respiratory distress (10) Low levels of vitamin D (10) Behavioral abnormality (9) Mental deterioration (9) Chronic pain (9) Congestive heart failure (8) Myocarditis (8) Type I diabetes mellitus (8) Sepsis (8) Infertility (7) Abnormality of the liver (7) Lymphopenia (7) Inflammation of the large intestine (7) Pulmonary obstruction (7) Pulmonary insufficiency (7) Immunodeficiency (6) Systemic lupus erythematosus (6) Chronic pulmonary obstruction (6) Abnormality of the gastrointestinal tract (6) Neoplasm of the lung (6) Encephalopathy (5) Obesity (5) Lymphoma (5) Autoimmunity (5) Breast carcinoma (5) Disseminated intravascular coagulation (5) Fatigue (5) Abnormality of the kidney (4) Coronary artery atherosclerosis (4) Cardiac arrest (4) Headache (4) Colon cancer (4) Arrhythmia (4) Carcinoma (4) Hypercoagulability (4) Autistic behavior (3) Seizure (3) Cardiomyopathy (3) Dysphagia (3) Migraine (3) Pulmonary arterial hypertension (3) Asthma (3) Bronchiectasis (3) Neoplasm of the pancreas (3) Psoriasiform dermatitis (3) Attention deficit hyperactivity disorder (3) Cutaneous melanoma (3) Neoplasm of head and neck (3) Pulmonary edema (3) Insomnia (3) Neoplasm of the large intestine (3) Renal insufficiency (2) Hypogeusia (2) Hearing impairment (2) Abnormality of the eye (2) Visual impairment (2) Conjunctivitis (2) Psychosis (2) Autism (2) Dementia (2) Abnormality of the endocrine system (2) Abnormality of the thyroid gland (2) Jaundice (2) Hepatic fibrosis (2) Premature birth (2) Abnormal heart morphology (2) Abnormality of blood and blood-forming tissues (2) Fever (2) Diarrhea (2) Hypothermia (2) Neurodegeneration (2) Abnormal intestine morphology (2) Alopecia of scalp (2) Encephalitis (2) Obstructive sleep apnea (2) Male infertility (2) Stillbirth (2) Paroxysmal atrial fibrillation (2) Lymphoid leukemia (2) Myeloproliferative disorder (2) Chronic lymphatic leukemia (2) Renal cell carcinoma (2) Multiple myeloma (2) Abnormal anterior horn cell morphology (2) Amyotrophic lateral sclerosis (2) Sleep apnea (2) Cystoid macular edema (2) Hemeralopia (2) Arteritis (2) Chronic kidney disease (2) Cervix cancer (2) Cholangitis (2) Cholangiocarcinoma (2) Myositis (2) Neuroendocrine neoplasm (2) Neoplasm of the rectum (2) Mania (2) Nephritis (1) Menorrhagia (1) Conductive hearing impairment (1) Cataract (1) Amblyopia (1) Periodontitis (1) Abnormality of the nervous system (1) Oligospermia (1) Adrenal insufficiency (1) Hyperaldosteronism (1) Abnormality of the skin (1) Lymphedema (1) Cholecystitis (1) Keratoconjunctivitis (1) Intellectual disability (1) Spastic diplegia (1) Hemiparesis (1) Meningitis (1) Cerebral hemorrhage (1) Abnormal joint morphology (1) Hepatic failure (1) Hepatocellular carcinoma (1) Intrauterine growth retardation (1) Hoarse voice (1) Dysphonia (1) Weak voice (1) Sudden cardiac death (1) Cor pulmonale (1) Tachycardia (1) Aortic valve stenosis (1) Bradycardia (1) Torsade de pointes (1) Atrioventricular block (1) Angina pectoris (1) Pancreatitis (1) Premature rupture of membranes (1) Weight loss (1) Thrombocytopenia (1) Autoimmune thrombocytopenia (1) Gastroesophageal reflux (1) Anorexia (1) Esophageal varix (1) Apnea (1) Status epilepticus (1) Subarachnoid hemorrhage (1) Memory impairment (1) Difficulty walking (1) Hyperkinetic movements (1) Alzheimer disease (1) Increased intracranial pressure (1) Colitis (1) Biliary cirrhosis (1) Hypotension (1) Vascular dilatation (1) Atherosclerosis (1) Osteoarthritis (1) Tachypnea (1) Hypoventilation (1) Myelodysplasia (1) Neoplasm of the liver (1) Hypokalemia (1) Hyponatremia (1) Hyperphosphatemia (1) Reduced factor VIII activity (1) Skeletal muscle atrophy (1) Myalgia (1) Muscular dystrophy (1) Neonatal death (1) Increased body weight (1) Neoplasm of the nervous system (1) Malnutrition (1) Thrombophlebitis (1) Ventricular tachycardia (1) Acute myeloid leukemia (1) Dilatation of the cerebral artery (1) Knee osteoarthritis (1) Monoclonal immunoglobulin M proteinemia (1) Intraalveolar phospholipid accumulation (1) Neoplasm of the stomach (1) Neoplasm of the genitourinary tract (1) Neoplasm of the skin (1) Female infertility (1) Benign prostatic hyperplasia (1) Hip osteoarthritis (1) Renal neoplasm (1) Uterine neoplasm (1) Testicular neoplasm (1) Intestinal atresia (1) Tonsillitis (1) Inflammatory abnormality of the skin (1) Placental abruption (1) Postprandial hyperglycemia (1) Endometrial carcinoma (1) Erythroid hypoplasia (1) Asterixis (1) Glioblastoma multiforme (1) B-cell lymphoma (1) Ciliary dyskinesia (1) Morphea (1) Allergy (1) Non-Hodgkin lymphoma (1) Retinal vein occlusion (1) Heart block (1) Dyspareunia (1) Ductal carcinoma in situ (1) Endometriosis (1) Cardiogenic shock (1) Vulvar neoplasm (1) Addictive behavior (1) Femur fracture (1) Neonatal sepsis (1) Glue ear (1) Neoplasm of the central nervous system (1) Abnormality of movement (1) Ulcerative colitis (1) Crohn's disease (1) Endocarditis (1) Toxemia of pregnancy (1) Neoplasm of the larynx (1) Ovarian neoplasm (1) Vaginal neoplasm (1) Cellulitis (1) Bulimia (1) Atelectasis (1) Esophageal neoplasm (1) Lymphocytosis (1) Polymenorrhea (1)

    HP:0002725: Systemic lupus erythematosus

    Developed by Shray Alag, The Harker School
    Sections: Correlations, Clinical Trials, and HPO

    Correlations computed by analyzing all clinical trials.

    Navigate: Clinical Trials and HPO

    Correlated Drug Terms (9)

    Name (Synonyms) Correlation
    drug481 Blood sampling Wiki 0.43
    drug2689 Questionnaire by phone call Wiki 0.41
    drug3067 Skin biopsy Wiki 0.41
    Name (Synonyms) Correlation
    drug572 COVID 19 Diagnostic Test Wiki 0.41
    drug618 COVID-19 infection Wiki 0.41
    drug3357 Throat swab Wiki 0.29
    drug3016 Serological test Wiki 0.24
    drug3285 Telemedicine Wiki 0.20
    drug3132 Standard care Wiki 0.14

    Correlated MeSH Terms (17)

    Name (Synonyms) Correlation
    D008180 Lupus Erythematosus, Systemic NIH 1.00
    D012859 Sjogren's Syndrome NIH 0.71
    D001167 Arteritis NIH 0.58
    Name (Synonyms) Correlation
    D011111 Polymyalgia Rheumatica NIH 0.47
    D013700 Giant Cell Arteritis NIH 0.47
    D012507 Sarcoidosis NIH 0.41
    D015535 Arthritis, Psoriatic NIH 0.41
    D001327 Autoimmune Diseases NIH 0.37
    D001168 Arthritis NIH 0.32
    D009220 Myositis NIH 0.29
    D001528 Behcet Syndrome NIH 0.29
    D025241 Spondylarthritis NIH 0.24
    D003095 Collagen Diseases NIH 0.14
    D001172 Arthritis, Rheumatoid NIH 0.12
    D012216 Rheumatic Diseases NIH 0.12
    D045169 Severe Acute Respiratory Syndrome NIH 0.02
    D018352 Coronavirus Infections NIH 0.01

    Correlated HPO Terms (5)

    Name (Synonyms) Correlation
    HP:0012089 Arteritis HPO 0.58
    HP:0002960 Autoimmunity HPO 0.37
    HP:0001369 Arthritis HPO 0.33
    Name (Synonyms) Correlation
    HP:0100614 Myositis HPO 0.29
    HP:0001370 Rheumatoid arthritis HPO 0.13

    Clinical Trials

    Navigate: Correlations   HPO

    There are 6 clinical trials

    1 COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases

    The trial is a prospective, observational study aiming to identify risk factors for serious COVID-19 infection by evaluating clinical measures and biomarkers of inflammation in patients with inflammatory rheumatic disease hospitalized with COVID-19 compared with control groups.

    1. Rheumatoid Arthritis
    2. Psoriatic Arthritis
    3. Axial Spondyloarthritis
    4. Systemic Lupus Erythematosus
    5. Giant Cell Arteritis
    1. Other: COVID-19 infection
    MeSH:Arthritis Arthritis, Psoriatic Rheumatic Diseases Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Collagen Diseases
    HPO:Arteritis Arthritis Polyarticular arthritis Systemic lupus erythematosus

    Primary Outcomes

    Description: The objective is to examine whether increased disease activity leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease

    Measure: Disease activity

    Time: Last registration of disease activity in the medical journal before admission/inclusion

    Secondary Outcomes

    Description: Examine whether immune modulating treatments protect or leads to increased risk of hospitalization due to COVID-19 in patients with inflammatory rheumatic disease.

    Measure: Immune modulating treatments

    Time: Current immune modulating treatments at admission/inclusion

    Description: Identify prognostic biomarkers by comparing serology of patients with inflammatory rheumatic disease hospitalized with COVID-19 and comparing them with the two control groups

    Measure: Biomarkers

    Time: Blood sample 1 is taken 0-3 days after inclusion and blood sample 2 is taken 2-6 weeks after blood sample 1
    2 Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease

    This epidemiological, transversal, cohort study aims to determine the potential influence of an active long-term hydroxychloroquine intake over the prevalence of a history of symptoms evocative of a COVID-19 infection in patients with a history of systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome or psoriatic arthritis, during the epidemic period in France. The information is gathered using a standardized questionnaire, by phone call.

    1. SARS-CoV-2
    2. Systemic Lupus Erythematosus
    3. Rheumatoid Arthritis
    4. Sjogren's Syndrome
    5. Psoriatic Arthritis
    1. Other: Questionnaire by phone call
    MeSH:Arthritis Arthritis, Psoriatic Sjogren's Syndrome Lupus Erythematosus, Systemic Autoimmune Diseases
    HPO:Arthritis Autoimmunity Polyarticular arthritis Systemic lupus erythematosus

    Primary Outcomes

    Description: Adjusted Odds Ratio measuring the association between an exposure to long-term hydroxychloroquine intake and a history of symptoms compatible with a COVID-19 infection.

    Measure: Adjusted Odds Ratio

    Time: 4 months after inclusion
    3 Manifestations Related to Covid-19 in Patients With Systemic Lupus Erythematosus

    The Covid-19 pandemic is a major public health issue. Potential treatments are essential to control the infection. Hydroxychlorquine is currently tested in several clinical trials to evaluate its efficiency.The objective of this study was to evaluate the symptoms related to COVID-19 occuring in patients with systemic lupus erythematosus (SLE)

    1. Systemic Lupus Erythematosus
    2. Covid-19
    MeSH:Lupus Erythematosus, Systemic
    HPO:Systemic lupus erythematosus

    Primary Outcomes

    Description: prevalence and severity of Covid-19 infection in patients with SLE

    Measure: prevalence and severity of Covid-19 infection in patients with SLE

    Time: 1 day

    Secondary Outcomes

    Description: prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine

    Measure: prevalence and severity of Covid-19 infection in patients treated by hydroxychloroquine

    Time: 1 day
    4 Use of Telemedicine for Follow-up of Systemic Lupus Erythematosus ("TeleSLE") in the COVID-19 Outbreak: a Pragmatic Randomised Controlled Trial

    Background Patients with systemic lupus erythematosus (SLE) might be more susceptible to Covid-19 due to the underlying disease, co-morbidities and the use of immunosuppressive drugs. The investigators hypothesize that telemedicine (TM) can be an effective mode of health-care delivery minimizing the risk of SARS-CoV-2 exposure, while maintaining disease control in these patients. Objectives The primary aim of this study is to evaluate the effectiveness to achieve remission or lupus low disease activity state (LLDAS) using TM delivered care compared to conventional in-person outpatient follow-up in SLE. The secondary objectives are to compare the patient reported outcomes and cost between the two modes of health care delivery. Study design This is a 12-months single centered pragmatic randomized controlled study. A total of 150 enrolled patients with SLE being followed at the Prince of Wales Hospital rheumatology clinics will be randomized to either TM (TM group) or standard care (SC group) in a 1:1 ratio. Patients in the TM group will receive scheduled follow-ups via videoconferencing using a custom-made mobile app. SC group patients will continue conventional standard in-person outpatient care. The disease and patient reported outcomes as well as the health care related costs will be compared. Expected outcomes Data from this study will support the notion that TM based care is as effective as conventional in-person care in achieving disease remission or LLDAS, as well as addressing psychosocial implications to ensure the best possible care for our patients in a cost-effective manner during this pandemic.

    1. SLE
    1. Other: Telemedicine
    2. Other: Standard care
    MeSH:Lupus Erythematosus, Systemic
    HPO:Systemic lupus erythematosus

    Primary Outcomes

    Measure: The percentage of patients in remission or LLDAS at one year.

    Time: 1 year

    Secondary Outcomes

    Measure: Direct and indirect costs after one year.

    Time: 1 year

    Description: LupusQoL evaluates 8 domains including physical health, pain, planning, intimate relationships, burden to others, emotional health, body image, and fatigue. Questionnaire has a 5-point Likert response format (0=all the time, 1=most of the time, 2=a good bit of the time, 3=occasionally, and 4=never). Higher score means better quality of life.

    Measure: The change of Lupus Quality of Life (LupusQoL) at one year.

    Time: 1 year

    Description: They are in a 5-point Likert response format (0=strongly disagree, 1=disagree, 2=neutral, 3=agree, and 4=strongly agree). Higher score means more confident and satisfied.

    Measure: Patient confidence and satisfaction score at one year.

    Time: 1 year

    Measure: Rates of adverse reaction and severe adverse reaction, including contracting COVID-19 infection, after one year.

    Time: 1 year

    Measure: Numbers of clinic visits, hospitalization, overall in-person hospital visits in one year.

    Time: 1 year

    Description: HAQ-DI covers various common daily activities to assess disability.It consists of 8 questions. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3). Higher score means higher disability.

    Measure: The change of (Health Assessment Questionnaire Disability Index HAQ-DI) at one year.

    Time: 1 year

    Description: HADS was developed to assess anxiety and depression in medical patients. Each domain has 7 items. Each item are answered by the patient on a four point (0-3) response category so the possible scores ranged from 0 to 21 for anxiety and 0 to 21 for depression. Higher score means more likely the patient has anxiety or depression.

    Measure: The change of (Hospital Anxiety and Depression Scale) HADS at one year.

    Time: 1 year
    5 Prevalence, Seroconversion and Impact of COVID-19 in Autoimmune Diseases in Europe

    The coronavirus disease 2019 (COVID-19) pandemic is a potentially fatal disease that represents a great global public health concern. In European countries such as Spain, Italy, Germany, Portugal, England and France, the pandemic has been of utmost importance. To date, no treatment has been robustly validated, and two theoretically opposite therapeutic strategies are proposed, based either on antiretroviral therapy or on immunomodulating agents. In this complex context, people living with immune-mediated inflammatory diseases (IMID) raise specific concerns due to their potentially increased risk of infections or of severe infections. Among IMID, Sjögren's syndrome, systemic lupus erythematosus, rheumatoid arthritis, spondyloarthritis and giant cell arteritis are some key diseases. In this cross-sectional, observational, multi-centric study, the investigators aim to assess both clinical and serological prevalence of COVID-19 among samples of IMID patients in Europe. In parallel, the investigators aim to compare the prevalence of COVID-19 seroconversion across these five IMIDs, their penetration across different 6 European countries (France, Italy, Spain, Germany, United Kingdom and Portugal), and to assess the severity of COVID-19 in these patients. Moreover, changes in treatment will be assessed, including immunomodulatory tapering or discontinuation, its causes over the outbreak period, as well as the incidence of IMID flares and their severity over this same period. Finally, patient's perceptions towards the pandemic will be evaluated and compared to medication beliefs. Data will be collected through questionnaires during medical visit or phone consultation and serological tests will be performed within routine blood collection. As so, all study procedures are comprised within usual care. Through this study the investigators expect to have a better knowledge of the clinical and serological prevalence of COVID-19 in IMID across Europe, along with the psychological, clinical, and therapeutic impact of COVID-19 in this particular patient population.

    1. COVID-19
    2. Systemic Lupus Erythematosus
    3. Sjogren's Syndrome
    4. Axial Spondyloarthritis
    5. Rheumatoid Arthritis
    6. Giant Cell Arteritis
    MeSH:Arthritis Arthritis, Rheumatoid Sjogren's Syndrome Spondylarthritis Polymyalgia Rheumatica Giant Cell Arteritis Arteritis Lupus Erythematosus, Systemic Autoimmune Diseases
    HPO:Arteritis Arthritis Autoimmunity Polyarticular arthritis Rheumatoid arthritis Systemic lupus erythematosus

    Primary Outcomes

    Description: ELISA tests for COVID-19 antibodies

    Measure: COVID-19 seroconversion

    Time: 1 day, during routine blood collection

    Description: Case report form filled by the health professional

    Measure: COVID-19 infection

    Time: During medical visit or phone consultation, up to 2 hours

    Secondary Outcomes

    Description: Descriptive analysis for each disease's rate

    Measure: Seroconversion rate by disease

    Time: 1 day, during routine blood collection

    Description: Descriptive analysis for each country's rate

    Measure: Penetration across Europe

    Time: 1 day, during routine blood collection

    Description: World Health Organization ordinal scale for clinical improvement at any given point of the infection, going from 0 to 8, where higher scores means worse outcome.

    Measure: COVID-19 severity

    Time: During medical visit, up to 1 hour

    Description: Descriptive analysis for overall and COVID-19-linked mortality rates

    Measure: COVID-19 mortality rate

    Time: During contact with family members, up to 1 hour

    Description: Case report form filled by the health professional

    Measure: COVID-19 impact on immunomodulatory treatment

    Time: During medical visit, up to 1 hour

    Description: Case report form filled by the patient

    Measure: Patient-reported flares

    Time: During medical visit, up to 1 hour

    Description: Fear of COVID-19 scale, going from 7 to 35, where higher scores means worse outcome.

    Measure: Patient's fears towards COVID-19

    Time: During medical visit, up to 1 hour

    Description: Beliefs about Medicines Questionnaire, going from 11 to 55, with higher scores indicating stronger beliefs regarding medicine.

    Measure: Patient's beliefs in their medicines towards COVID-19

    Time: During medical visit, up to 1 hour
    6 Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases

    An observational study aiming to assess the serological profile of SARS-Cov2 patients with systemic diseases such as systemic lupus erythematosus, Sjogren syndrome, sarcoidosis, inflammatory myopathies, Behçet's disease, Rheumatoid arthritis and Spondyloarthritis

    1. SARS-CoV Infection
    2. Systemic Disease
    3. Systemic Lupus Erythematosus
    4. Sjogren's Syndrome
    5. Sarcoidosis
    6. Inflammatory Myopathy
    7. Behçet Disease
    8. Rheumatoid Arthritis
    9. Spondyloarthritis
    1. Diagnostic Test: Serological test
    MeSH:Coronavirus Infections Severe Acute Respiratory Syndrome Sjogren's Syndrome Myositis Behcet Syndrome Sarcoidosis Lupus Erythematosus, Systemic
    HPO:Inflammatory myopathy Myositis Systemic lupus erythematosus

    Primary Outcomes

    Description: Number of patients with positive serological test of SARS Cov2

    Measure: Serological Profile

    Time: Inclusion

    HPO Nodes


    Data processed on December 13, 2020.

    An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

    Drug Reports   MeSH Reports   HPO Reports  


    4,818 reports on interventions/drugs


    706 reports on MeSH terms


    306 reports on HPO terms

    All Terms

    Alphabetical index of all Terms

    Google Colab

    Python example via Google Colab Notebook